XML 36 R26.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2021
Revenue from Contract with Customer [Abstract] |
Schedule of Total Revenue by Product and by U.S versus Rest of World | The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):
| Three months ended June 30,
| 2021 |  | 2020
(in millions) | U.S. |  | RoW |  | Total |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 73.8 |  |  | $ | 12.2 |  |  | $ | 86.0 |  |  | $ | 34.9 |  |  | $ | 5.0 |  |  | $ | 39.9 |
Tumor Profiling | 18.1 |  |  | 11.1 |  |  | 29.2 |  |  | 8.6 |  |  | 1.9 |  |  | 10.5 |
Prenatal | 29.2 |  |  | 0.2 |  |  | 29.4 |  |  | 16.5 |  |  | 0.1 |  |  | 16.6 |
Pharmacogenomics | 22.6 |  |  | — |  |  | 22.6 |  |  | 8.5 |  |  | — |  |  | 8.5 |
Autoimmune | 10.2 |  |  | — |  |  | 10.2 |  |  | 7.3 |  |  | — |  |  | 7.3 |
Other | 0.2 |  |  | 1.1 |  |  | 1.3 |  |  | 0.5 |  |  | — |  |  | 0.5 |
Total molecular diagnostic revenue | 154.1 |  |  | 24.6 |  |  | 178.7 |  |  | 76.3 |  |  | 7.0 |  |  | 83.3 |
Pharmaceutical and clinical service revenue | 10.7 |  |  | — |  |  | 10.7 |  |  | 9.9 |  |  | — |  |  | 9.9 |
Total revenue | $ | 164.8 |  |  | $ | 24.6 |  |  | $ | 189.4 |  |  | $ | 86.2 |  |  | $ | 7.0 |  |  | $ | 93.2 |
| Six months ended June 30,
| 2021 |  | 2020
(in millions) | U.S. |  | RoW |  | Total |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 138.9 |  |  | $ | 23.2 |  |  | $ | 162.1 |  |  | $ | 116.2 |  |  | $ | 8.9 |  |  | $ | 125.1 |
Tumor Profiling | 42.3 |  |  | 17.9 |  |  | 60.2 |  |  | 19.3 |  |  | 4.9 |  |  | 24.2 |
Prenatal | 52.8 |  |  | 0.3 |  |  | 53.1 |  |  | 36.7 |  |  | 0.2 |  |  | 36.9 |
Pharmacogenomics | 40.2 |  |  | — |  |  | 40.2 |  |  | 28.9 |  |  | — |  |  | 28.9 |
Autoimmune | 20.9 |  |  | — |  |  | 20.9 |  |  | 17.7 |  |  | — |  |  | 17.7 |
Other | 0.2 |  |  | 1.6 |  |  | 1.8 |  |  | 1.0 |  |  | — |  |  | 1.0 |
Total molecular diagnostic revenue | 295.3 |  |  | 43.0 |  |  | 338.3 |  |  | 219.8 |  |  | 14.0 |  |  | 233.8 |
Pharmaceutical and clinical service revenue | 24.2 |  |  | — |  |  | 24.2 |  |  | 19.5 |  |  | 3.9 |  |  | 23.4 |
Total revenue | $ | 319.5 |  |  | $ | 43.0 |  |  | $ | 362.5 |  |  | $ | 239.3 |  |  | $ | 17.9 |  |  | $ | 257.2 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
| Six months ended June 30,
(in millions) | 2021 |  | 2020
Deferred revenue - beginning balance | $ | 32.7 |  |  | $ | 3.6 |
Revenue recognized | (15.5) |  |  | (6.1) |
Prepayments | 6.3 |  |  | 35.3 |
Held for sale reclassification | (0.9) |  |  | — |
Deferred revenue - ending balance | $ | 22.6 |  |  | $ | 32.8 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration